Introduction to Drug-Device Combination Products: What They Are and Why Development Is Different
19 Aug 2026
Modern healthcare products are increasingly designed to do more than simply deliver a medicine or perform a medical function. A device may be designed to deliver a drug, a drug may depend on a device to achieve its intended therapeutic effect, or both may be developed together as one integrated product.
This approach can provide important benefits for patients, including more controlled drug delivery, improved treatment convenience, targeted therapy, and better management of certain clinical conditions. However, combining a drug and a device also introduces a level of development complexity that does not normally exist when the two products are developed independently.
A drug-device combination product therefore cannot be treated simply as a drug plus a device. The interaction between the two constituent parts, their intended use, the patient population, the method of administration, and the applicable regulatory requirements all need to be considered as part of the overall product development process.
What is a drug-device combination product?
A drug-device combination product is broadly a healthcare product in which a drug and a medical device are combined, packaged, or intended to be used together to achieve the intended therapeutic purpose.
Under the U.S. regulatory framework, combination products can include products in which regulated components are physically or chemically combined into a single entity, products in which drug and device components are packaged together, and certain separately packaged products that are specifically intended to be used together.
The individual components are often referred to as constituent parts. A combination product may therefore contain a drug constituent part and a device constituent part, with each bringing its own characteristics, requirements, and potential risks.
Some familiar examples include:
- Prefilled syringes: A medicinal product is supplied in a syringe that functions as the delivery device.
- Autoinjectors: A drug is combined with an automated injection mechanism designed to deliver the required dose.
- Drug-eluting stents: A medical device provides a structural function while also releasing a therapeutic substance at the treatment site.
- Drug-delivery systems: Devices such as inhalers, infusion systems, and other delivery technologies may be designed specifically around the characteristics of the drug being administered.
- Drug-containing wound dressings: The dressing provides a physical function while a medicinal substance provides an additional therapeutic function.
The important point is that the device and drug are not necessarily independent products simply because each component could exist separately.
Why are combination products different?
A conventional medical device is generally developed around device requirements such as intended use, performance, safety, usability, materials, manufacturing, and risk management. A pharmaceutical product, on the other hand, has its own requirements relating to formulation, stability, potency, purity, manufacturing, dosage, and therapeutic performance. A combination product brings these considerations together.
This creates several questions that would not normally arise to the same extent for a conventional drug or device:
- Does the device deliver the correct amount of drug?
- Does the drug affect the performance or materials of the device?
- Can the device continue to perform correctly throughout the product’s shelf life?
- Does the combination remain safe and effective when used by the intended patient?
- Are the drug and device risks being evaluated together?
- Which regulatory requirements apply to the finished combination product?
These questions demonstrate why combination-product development requires coordination between pharmaceutical, engineering, quality, regulatory, clinical, and human-factors disciplines.
1. Understand the constituent parts
The first step is to clearly identify what makes up the combination product. The drug and device should not be considered only as physical components. Each constituent part may have its own design requirements, manufacturing processes, specifications, risks, and controls. For example, in a prefilled syringe, the medicinal product is one constituent part while the syringe, stopper, needle, and associated components form part of the delivery system.
The development team therefore needs to understand both parts and, more importantly, how they interact.
2. Define the intended use of the complete product
The intended use should be considered at the level of the complete combination product.
What is the product intended to achieve? Who will use it? Under what conditions will it be used? What role does the device play in achieving the intended therapeutic outcome?
For example, an autoinjector may not simply be a mechanism for holding a drug. Its ability to deliver the intended dose, at the required rate and through the intended route of administration, can be an important part of the overall product performance.
This means that intended use, user needs, and product requirements need to be established with both constituent parts in mind.
3. Evaluate the interaction between drug and device
This is one of the most important differences between conventional product development and combination-product development.
A drug may interact with the materials used in the device. Similarly, the device may influence the way the drug is stored, handled, delivered, or released.
Consider a syringe used to contain a medicinal product. Material compatibility, container closure, extractables and leachables, lubrication, and drug stability may all become relevant to the overall product.
The question is therefore not only, “Is the drug safe?” or “Is the device safe?”
The more important question is:
Is the drug-device combination safe and effective when used as intended?
4. Consider the complete development lifecycle
Combination-product development should be managed from the early concept stage through commercialization and lifecycle management.
This includes activities such as:
- user needs and intended use;
- design inputs and outputs;
- risk management;
- human factors engineering;
- design verification;
- design validation;
- test method development;
- packaging and compatibility studies;
- manufacturing development;
- design transfer;
- process validation; and
- post-market monitoring.
A weakness in one area can affect another.
For example, a change in the device material may affect compatibility with the drug. A change in the drug formulation may affect delivery performance. A manufacturing change may alter a critical characteristic of the device and consequently affect the delivered dose.
This is why lifecycle thinking is particularly important for combination products.
5. Integrate risk management
Risk management becomes more complex when two regulated product types are combined.
A conventional device risk assessment may focus primarily on hazards associated with the device. A pharmaceutical risk assessment may focus on characteristics of the medicinal product.
For a combination product, the development team should also consider risks arising at the interface.
Examples include:
- incorrect dose delivery;
- interaction between drug and device materials;
- changes in drug delivery performance;
- usability-related errors;
- device malfunction affecting therapy;
- degradation or contamination;
- packaging or transportation effects; and
- changes in performance over the product lifecycle.
The risk management process therefore needs to provide a complete view of the product rather than treating the constituent parts as completely independent.
6. Integrate human factors and usability
A combination product can be technically safe and still create risks if users cannot operate it correctly. This is particularly important for products such as autoinjectors, pen injectors, inhalers, infusion systems, and other delivery devices.
The intended user may be a trained healthcare professional, a patient, or a caregiver. Each user group may have different capabilities, environments, and potential use errors. For example, a patient using an injection device at home may have to identify the correct product, prepare it, position it correctly, activate the mechanism, and confirm that the dose has been delivered. Human factors engineering should therefore consider the complete use process and its relationship with the drug and device.
7. Establish the appropriate regulatory pathway
One of the major challenges associated with combination products is that drug and device components may traditionally fall under different regulatory frameworks.
In the United States, the FDA’s combination-product framework addresses products involving drugs, devices, and/or biological products. The regulatory approach can depend on the type of combination and, in relevant cases, the primary mode of action (PMOA). Different regulatory pathways may consequently apply depending on whether the drug, device, or another constituent provides the primary therapeutic action.
This regulatory determination can influence development planning, testing, submission strategy, manufacturing controls, and post-market responsibilities. Therefore, regulatory strategy should not be left until the final stages of product development.
8. Establish controls for manufacturing and lifecycle changes
The development process does not end when the combination product is approved. Manufacturing controls need to consider both constituent parts and the processes used to bring them together. For example, when different organizations manufacture the drug and device components, responsibilities for specifications, change control, supplier management, deviations, complaints, and post-market information need to be clearly established.
A change that appears minor from the perspective of one constituent part may have a significant effect on the finished combination product. A change in device material, for example, may affect drug compatibility. A change in the drug formulation may influence delivery performance. This is why lifecycle management and change control are particularly important for combination products.
Why integrated development matters
The greatest challenge in combination-product development is not simply meeting the requirements for a drug and meeting the requirements for a device. The challenge is demonstrating that the complete product works safely and effectively as intended.
A combination product may have individually acceptable constituent parts but still present problems when those parts are brought together. The interaction between materials, formulation, delivery mechanism, packaging, user behavior, manufacturing processes, and clinical use can create risks that would not be identified by looking at one constituent part alone. This is why an integrated development approach is essential.
Partner with TS Quality & Engineering
Drug-device combination products provide an important opportunity to improve how therapies are delivered and how patients receive treatment. They can combine the therapeutic benefits of a medicinal product with the functional advantages of a medical device, creating solutions that may not be possible through either product type alone. At the same time, this combination introduces additional development responsibilities. The organization needs to understand the constituent parts, define the intended use of the complete product, evaluate drug-device interactions, integrate risk management and human factors, establish appropriate verification and validation activities, and maintain effective controls throughout manufacturing and the product lifecycle. The most successful combination-product development programs therefore do not ask only whether the drug is acceptable or whether the device is acceptable.
They ask a more important question:
Can the complete drug-device system consistently deliver the intended benefit, safely and effectively, when used by the intended user? Answering that question from the beginning of development provides a stronger foundation for product quality, regulatory compliance, manufacturing readiness, and ultimately patient safety.
Navigating the complex interface between drug stability, device performance, and regulatory compliance requires specialized, integrated expertise. At TS Quality & Engineering, we help life sciences organizations bridge the gap between pharmaceutical standards and medical device requirements. From initial risk assessment and human factors integration to verification, validation, and post-market lifecycle support, our team ensures your combination product moves seamlessly from concept to compliance.
- Integrated Quality Systems: Unifying ISO 13485 device controls with GMP pharmaceutical standards.
- Lifecycle & Risk Management: Addressing interface risks early to prevent costly delays.
- Regulatory Readiness: Crafting clear strategies tailored to primary mode of action (PMOA) requirements.
Ensure your complete drug-device system is safe, effective, and compliant from day one.
Contact TS Quality & Engineering today to discuss your combination product roadmap.
ScienceDirect (n.d.) Drug-device combination product. Available at: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/drug-device-combination-product (Accessed: 24 August 2026).
